Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2018-04-18 Proxy Solicitation & In…
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It contains detailed information about the Annual General Meeting (AGM) of shareholders, including proposals for voting on the annual report, election and re-election of board members, compensation approvals, share capital increases, and other governance matters. The document is not the annual report itself but rather the proxy materials related to the AGM. The presence of voting proposals and instructions confirms it is a Proxy Solicitation & Information Statement. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a full proxy statement.
2018-04-18 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-18 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a "Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934." It contains detailed information about the upcoming 2018 Annual General Meeting of Shareholders for CRISPR Therapeutics AG, including agenda items such as election and re-election of board members, approval of compensation, share capital changes, and auditor re-election. The document is not the annual report itself but a solicitation of shareholder votes and information related to the AGM. It also references the availability of the annual report and Form 10-K elsewhere, indicating this document is for proxy solicitation purposes. Therefore, the document fits the definition of Proxy Solicitation & Information Statement (PSI).
2018-04-02 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-15 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.